Savara to Present at Jefferies Healthcare Conference

Rhea-AI Summary

Savara Inc. (NASDAQ: SVRA), a biopharmaceutical company focused on rare respiratory diseases, announced its management team will present at the Jefferies Healthcare Conference on June 8, 2022, at 1:00 pm ET in New York City. A live webcast will be available on the company's website and archived for 90 days. Savara's lead program, molgramostim, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP) and utilizes the investigational eFlow® Nebulizer System.

AUSTIN, Texas--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies Healthcare Conference on June 8, 2022 at 1:00 pm ET in New York City. A live webcast of the presentation will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005834/en/

Savara Inc. IR & PR

Anne Erickson

Senior Vice President, Chief of Staff

anne.erickson@savarapharma.com

(512) 851-1366

Source: Savara Inc.

FAQ

What is Savara Inc. presenting at the Jefferies Healthcare Conference?

Savara Inc. will present information about its clinical programs and focus on rare respiratory diseases.

When is Savara Inc. scheduled to present at the Jefferies Healthcare Conference?

Savara Inc. is scheduled to present on June 8, 2022, at 1:00 pm ET.

Where can I watch Savara Inc.'s presentation at the Jefferies Healthcare Conference?

The presentation will be available via live webcast on Savara's website.

What is the focus of Savara Inc.'s lead program?

Savara's lead program focuses on molgramostim, which is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

What technology does Savara Inc. use for delivering molgramostim?

Molgramostim is delivered via the investigational eFlow® Nebulizer System.